Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates
07:06pm, Monday, 11'th May 2026
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.68 per share a year ago.
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
04:12pm, Monday, 11'th May 2026
Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No F
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
11:25am, Monday, 11'th May 2026
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
11:25am, Monday, 11'th May 2026
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders a
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of C
Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
04:02pm, Thursday, 07'th May 2026
CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, deve
Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:20am, Thursday, 07'th May 2026
Get a deeper insight into the potential performance of Catalyst (CPRX) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some
Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
10:00am, Thursday, 07'th May 2026
MILWAUKEE , May 7, 2026 /PRNewswire/ -- Ademi LLP is investigating Catalyst (NASDAQ: CPRX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction w
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) to Angelini Pharma S.p.A. for $31.50 per share in c
Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal
03:15am, Thursday, 07'th May 2026
The move marks Italy's Angelini Pharma's entry into the U.S. market.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
02:44am, Thursday, 07'th May 2026
As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla. , May 07
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
02:44am, Thursday, 07'th May 2026
As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla.
Italy's Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
02:24am, Thursday, 07'th May 2026
Italy's Angelini Pharma said on Thursday it has agreed to acquire Catalyst Pharmaceuticals for $4.1 billion.
The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration
Will Catalyst (CPRX) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Monday, 04'th May 2026
Catalyst (CPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
